Sort Results:
List of Materials
 |
Addressing Irreproducibility Presentations: Welcome and Outline of the DayBarbara Slusher and Sitta Sittampalam were the opening presenters at the ADDC/AGM Symposium Addressing Irreproducibility in Target Validation. They offered background on both the ADDC and the Assay Guidance Manual as well as meeting objectives... |
Academic Drug Discovery Consortium/ Assay Guidace Manual Johns Hopkins Brain Science Institute/ NCATS Presenter: Barbara Slusher & G. Sitta Sittampalam |
|
Alternative Approaches To Lead GenerationHistorically, drug discovery was chiefly an empirical enterprise, with the shift to a more hypothesis-driven approach occurring in the 20th century. Whereas originally drug discovery was focused primarily on identifying therapeutically useful agents... |
University of Kansas Medical Center Presenter: S.J. Enna, Ph.D. |
|
Changing Landscape of Drug Discovery in Industry SettingsThis lecture entitled “Changing Landscape of Drug Discovery in Industry Settings†introduces the drug discovery and development process to a class focused on a range of topics related to discovery and development of new therapeutic agents... |
Vanderbilt Center for Neuroscience Drug Discovery Vanderbilt University Presenter: P. Jeffrey Conn |
|
CNS Medicinal Chemistry: Introduction and a Case Study – GlyT1This lecture will provide an overview of the drug discovery process with specific attention being paid to the role of medicinal chemistry, and key issues for the CNS disease-focused medicinal chemist (Lipinski’s rules, CNS penetration, transporter... |
Vanderbilt Specialized Chemistry Center (MLPCN) Vanderbilt University Presenter: Craig W. Lindsley |
|
Drug Discovery and the Biopharmaceutical Ecosystem: The Imperative for New R&D Models “The Evolving Role of Academic Drug Discovery”This presentation by Dr. Steven Paul was the keynote address for the "Johns Hopkins Brain Science Institute's Drug Discovery in Academia: The new paradigm in drug discovery" conference.' |
Weill Cornell Medical College of Cornell University Presenter: Steven M. Paul, M.D. |
|
Drug-Like Properties and Druggable TargetsA lecture discussing the concept of drug-like molecular properties, druggable targets, and chemical space. |
Brain Science Institute NeuroTranslational Drug Discovery Program Johns Hopkins University Presenter: Takashi Tsukamoto, Ph.D. |
|
First-In-Man - risk assessmentThe example of TeGenero first-in-man case study was used to explore the usability of systems theoretic accident modeling and processes (STAMP) to create control structure of selected critical points in drug development, approval and... |
ARETE-ZOE, LLC Presenter: Veronika Valdova |
|
Formulation and Route of AdministrationIn order to exert the desired effect in a proof-of-concept animal study, a drug molecule or development candidate first of all needs to be bioavailable and lack of solubility therefore often poses the first barrier to successful translation a... |
Department of Pharmacology UC Davis Presenter: Heike Wulff, Ph.D. |
|
Funding Academic Drug DiscoveryThe NIH supports drug discovery and development for nervous system disorders through a variety of programs. Some provide funding through grants or cooperative agreements to support specific stages of research and development, for particular disease... |
NINDS Office of Translational Research Presenter: Rebecca Farkas, Ph.D. |
|
Hit to Lead to CandidateOnce a drug target has been identified and assays developed, hits (compounds with confirmed activity at the target) are obtained from many sources - often from high-throughput screening. Drug discovery scientists investigate the hits by obtaining or... |
Johns Hopkins School of Medicine Presenter: Jim Barrow, Ph.D. |